Acuta Capital Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Acuta Capital Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-770,000	Closed	-$11.2M	–	48
2020 Q1	$11.2M	Sell	770,000 -287,500	-27%	-$5.07M	5.42%	6
2019 Q4	$21.4M	Buy	1,057,500 +207,500	+24%	+$1.91M	5.31%	5
2019 Q3	$4.54M	Sell	850,000 -85,000	-9%	-$514K	3.28%	12
2019 Q2	$6.15M	Buy	+935,000	New	+$5.96M	2.19%	18
2017 Q2	–	Sell	-400,000	Closed	-$2.94M	–	63
2017 Q1	$2.94M	Sell	400,000 -600,000	-60%	-$2.77M	0.7%	35
2016 Q4	$2.1M	Buy	+1,000,000	New	+$3.22M	0.78%	27
2015 Q4	–	Sell	-377,427	Closed	-$1.07M	–	57
2015 Q3	$1.07M	Sell	377,427 -147,324	-28%	-$505K	0.62%	41
2015 Q2	$1.58M	Buy	524,751 +94,751	+22%	+$352K	0.98%	29
2015 Q1	$1.88M	Buy	+430,000	New	+$1.7M	1.58%	22

Other funds holding AUPH

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Acuta Capital Partners's AUPH Position: Q2 2020 in Review

Acuta Capital Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2020, closing a stake of 770,000 shares — an estimated $11.2M sold.

Acuta Capital Partners first reported a position in AUPH in Q1 2015 and held it in 9 quarters. The position peaked at $21.4M in Q4 2019. 132 funds tracked by Wall St. Rank hold AUPH as of Q2 2020.

Acuta Capital Partners reported no remaining Aurinia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Acuta Capital Partners sold 770,000 Aurinia Pharmaceuticals shares in Q2 2020, an estimated $11.2M.
Acuta Capital Partners first reported a position in Aurinia Pharmaceuticals in Q1 2015 and held it in 9 quarters.
Acuta Capital Partners's Aurinia Pharmaceuticals position peaked at $21.4M in Q4 2019.
132 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2020.

Based on Acuta Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.